Exscientia
Founded Year
2012Stage
IPO | IPOTotal Raised
$673.7MDate of IPO
10/1/2021Revenue
$0000About Exscientia
Exscientia (NASDAQ: EXAI) is an AI-driven, drug discovery, and design enterprise. Exscientia aims to use AI to discover and design better quality drugs with greater efficiency.
Missing: Exscientia's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Exscientia's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Research containing Exscientia
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned Exscientia in 7 CB Insights research briefs, most recently on Dec 12, 2022.
Expert Collections containing Exscientia
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Exscientia is included in 5 Expert Collections, including Artificial Intelligence.
Artificial Intelligence
10,622 items
This collection includes startups selling AI SaaS, using AI algorithms to develop their core products, and those developing hardware to support AI workloads.
Omics
1,267 items
Companies involved in the capture, sequencing, and/or analysis of genomic, transcriptomic, proteomic, and/or metabolomic data
Digital Health
10,069 items
The digital health collection includes vendors developing software, platforms, sensor & robotic hardware, health data infrastructure, and tech-enabled services in healthcare. The list excludes pureplay pharma/biopharma companies and and assistive tech developers.
Biopharma Tech
838 items
Drug Discovery Tech Market Map
221 items
This CB Insights Tech Market Map highlights 220 drug discovery companies that are addressing 12 distinct technology priorities that pharmaceutical companies face.
Exscientia Patents
Exscientia has filed 1 patent.
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
6/4/2019 | Adenosine receptor antagonists, Carbamates, Xanthines, Acetylcholinesterase inhibitors, Purines | Application |
Application Date | 6/4/2019 |
|---|---|
Grant Date | |
Title | |
Related Topics | Adenosine receptor antagonists, Carbamates, Xanthines, Acetylcholinesterase inhibitors, Purines |
Status | Application |
Latest Exscientia News
May 3, 2023
OXFORD, England--(BUSINESS WIRE)--Exscientia plc (Nasdaq: EXAI) today announced the appointment of Professor Franziska Michor, Ph.D. to its Board of Directors. Prof. Michor is a professor of Computational Biology in the Department of Data Science at the Dana-Farber Cancer Institute, in the Department of Biostatistics at the Harvard T.H. Chan School of Public Health, and in the Department of Stem Cell and Regenerative Biology at Harvard University. The Board now comprises seven directors. “We ar
Exscientia Frequently Asked Questions (FAQ)
When was Exscientia founded?
Exscientia was founded in 2012.
Where is Exscientia's headquarters?
Exscientia's headquarters is located at The Schrodinger Building, Oxford.
What is Exscientia's latest funding round?
Exscientia's latest funding round is IPO.
How much did Exscientia raise?
Exscientia raised a total of $673.7M.
Who are the investors of Exscientia?
Investors of Exscientia include Bill & Melinda Gates Foundation, Novo Holdings, GT Healthcare Capital Partners, Bristol-Myers Squibb, BlackRock and 15 more.
Who are Exscientia's competitors?
Competitors of Exscientia include Enveda Biosciences, Brightseed, Iktos, Antiverse, BERG, Quris AI, Biorelate, Cyclica, nference, Causaly and 37 more.
Compare Exscientia to Competitors
insitro is a data-driven drug discovery and development company that leverages machine learning and high-throughput biology to transform the way medicines are created to help patients.
Atomwise uses deep learning and artificial intelligence (AI)-based neural networks to help discover new medicines. It predicts drug candidates for pharmaceutical companies, start-ups, and research institutions and designs drugs using computational drug design. The company was founded in 2012 and is based in San Francisco, California.
Cyclica offers artificial intelligence (AI) and computational biophysics based drug discovery process. Its structure-based and artificial intelligence (AI) augmented drug discovery platform includes Ligand Design for multi-targeted and multi-objective drug design, and Ligand Express for off-target profiling, systems biology linkages, and structural pharmacogenomic insights. The company was founded in 2013 and is based in Toronto, Canada.
Healx provides drug discovery services. The company manufactures drugs using technology to bring treatments for rare diseases to patients. Its platform, Healnet, helps face challenges by analyzing drug and disease data points. The company was founded in 2014 and is based in Cambridge, U.K.
Aitia is a health tech company using Causal AI and Digital Twins to discover the next generation of breakthrough drugs. By leveraging the convergence of multi-omic patient data, high-performance computing, and causal learning and AI, Aitia is revealing the hidden biological mechanisms of disease to create Digital Twins of disease in oncology, neurodegenerative disorders, and immunology. Gemini Digital Twins are being used today to discover novel therapies and accelerate R&D in multiple myeloma, prostate cancer, Alzheimer’s Disease, Parkinson’s Disease, and Huntington’sDisease, with several more in development. Aitia’s partners include pharmaceutical companies, academic research and medical centers, medical societies, multi-omic data companies, and patient advocacy groups globally. Aitia was formerly GNS Healthcare and rebranded in January 2023. Aitia was founded in 2000 and is based in Somerville, Massachusetts.
Aria Pharmaceuticals is a preclinical-stage pharmaceutical company that discovers and develops novel small molecule therapies for complex and hard-to-treat diseases
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.